Oncolytic virotherapy for gliomas: A preclinical and clinical summary

Naiara Martínez-Vélez, Candelaria Gomez-Manzano, Juan Fueyo, Ana Patiño-García, Marta M. Alonso

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations

Abstract

Gliomas are the most common and aggressive brain tumors and despite advances in their therapeutic management they remain fatal. Radically, different therapeutic approaches are needed to treat this aggressive disease. Oncolytic viruses that intrinsically kill cancer cells or that have been genetically engineered to specifically destroy this population are becoming a viable therapeutic options for gliomas. A number of preclinical studies have demonstrated the efficacy of oncolytic viruses as a therapeutic strategy for gliomas. Those studies have led to a number of clinical trials using oncolytic virus for glioma treatment. In this chapter, we review the different viruses (adenovirus, herpes virus, parvovirus, poliovirus, reovirus, newcastle disease virus, retrovirus, and measles viruses) that have been evaluated preclinically and clinically for the treatment of glioma.

Original languageEnglish (US)
Title of host publicationGene Therapy in Neurological Disorders
PublisherElsevier
Pages357-384
Number of pages28
ISBN (Electronic)9780128098134
ISBN (Print)9780128098219
DOIs
StatePublished - Jan 1 2018

Keywords

  • Clinical trial
  • Glioma
  • Glioma treatment
  • Oncolytic virus

ASJC Scopus subject areas

  • General Medicine
  • General Neuroscience

Fingerprint

Dive into the research topics of 'Oncolytic virotherapy for gliomas: A preclinical and clinical summary'. Together they form a unique fingerprint.

Cite this